Progestins — CPB 0510 | AETNA Coverage Update

Aetna, a CVS Health company, modified CPB 0510 covering progestins, effective September 26, 2025. Here's what billing teams need to know before submitting claims.

Aetna updated its progestins coverage policy under CPB 0510 Aetna system, refining medical necessity criteria across etonogestrel subdermal implants, medroxyprogesterone acetate injections, and progesterone injections. The primary codes affected include HCPCS J7307, J1050, J2675, and CPT 11976, 58300, and 58301, along with the full suite of levonorgestrel IUD codes. If your practice bills any of these, the updated criteria change how you document and support claims.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Progestins — CPB 0510
Policy Code	CPB 0510
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	Medium-High
Specialties Affected	OB/GYN, Reproductive Endocrinology, Adolescent Medicine, Oncology, Gender-Affirming Care
Key Action	Audit documentation for all progestin injection and implant claims against updated medical necessity criteria before submitting after September 26, 2025

---

Aetna Progestins Coverage Criteria and Medical Necessity Requirements 2025

The Aetna progestins coverage policy under CPB 0510 covers three distinct product categories. Each has its own medical necessity rules. Treat them separately — conflating them is how you get denials.

Etonogestrel Subdermal Implant (Nexplanon — HCPCS J7307)

Aetna covers J7307 for two indications. The first is pregnancy prevention. The second — and this is the notable one — is management of primary dysmenorrhea or secondary dysmenorrhea associated with endometriosis in adolescent members. That second indication is specific: it must be an adolescent, and the dysmenorrhea must be primary or secondary to endometriosis. ICD-10 codes N94.4, N94.5, N94.6, and the N80.x endometriosis codes are your documentation anchors here.

Check benefit plan descriptions before billing J7307 for contraception. Many Aetna plans exclude contraceptive coverage outright. A clean claim for pregnancy prevention still hits a benefit exclusion wall if the plan doesn't cover contraceptives. This is a plan-level issue, not a medical necessity issue — your denial will read differently depending on which wall you hit.

Medroxyprogesterone Acetate Injection (HCPCS J1050)

Depo-Provera CI and its generic 150 mg/mL formulation (billed as J1050) cover two indications. Contraception is the first — same plan exclusion caveat applies. Gender dysphoria is the second, and it carries a five-part criteria checklist.

Every one of these five criteria must be met: confirmed gender dysphoria diagnosis (F64.x codes), capacity for informed consent to hormone therapy, reasonably controlled comorbidities, patient education on contraindications and side effects, and — for members under 18 — prescription by or in consultation with a provider who specializes in transgender youth care and has collaborated with a mental health provider.

That last criterion is the one most claims miss. If you're billing J1050 for gender dysphoria in a minor, your documentation needs to show the specialty provider connection and the mental health collaboration. Missing either one is a direct path to claim denial.

Depo-Provera 400 mg/mL is a separate story — and a mostly moot one. Aetna covers the 400 mg/mL formulation as adjunctive palliative therapy for inoperable, recurrent, or metastatic endometrial or renal carcinoma. But the FDA discontinued that formulation on October 27, 2020. You likely won't see active claims here, but flag it if you're working with oncology billing.

Progesterone Injection (HCPCS J2675)

Aetna covers progesterone intramuscular injection (J2675) for one indication: amenorrhea or abnormal uterine bleeding due to hormonal imbalance, in the absence of organic pathology. "Absence of organic pathology" is the phrase your documentation needs to address directly. ICD-10 codes N91.0–N93.9 cover the menstrual disorder range. If there's a documented fibroid or uterine cancer, this indication no longer applies — and Aetna will look for that.

Prior authorization requirements for these products vary by plan. Verify prior auth status for J7307, J1050, and J2675 at eligibility check. Don't assume a prior auth that covered a previous fill is still active under the updated criteria.

---

Aetna Progestins Exclusions and Non-Covered Indications

This is where CPB 0510 is most explicit — and where your claim denials will concentrate if documentation is thin.

Aetna considers etonogestrel subdermal implant (J7307) experimental, investigational, or unproven for all indications except pregnancy prevention and adolescent dysmenorrhea/endometriosis. Any other use — including off-label management of conditions like PCOS or abnormal uterine bleeding in adult members — won't get covered.

Progesterone IM injection (J2675) has the longest exclusion list. Aetna considers it experimental for all of these:

The twin pregnancy indication is the one that surprises people. If a high-risk OB practice has been billing J2675 for prematurity prevention in twins, that's denied under this policy. Reimbursement on those claims is at risk if documentation doesn't support the one covered indication.

Progesterone subcutaneous injection is also experimental per this policy. That's distinct from IM — if your provider is administering subcutaneously and billing J2675, that's a problem. The covered route of administration is intramuscular only.

Medroxyprogesterone acetate IM is experimental for all indications not listed above. Oral medroxyprogesterone acetate falls under the pharmacy benefit — don't bill J1050 for an oral formulation. Route matters for both coverage and billing guidelines here.

---

Coverage Indications at a Glance

---

Aetna Progestins Billing Guidelines and Action Items 2025

Copy Action Items

If your practice has a significant volume of progesterone injection claims for high-risk OB — especially twin pregnancies — talk to your compliance officer before the effective date of September 26, 2025. The policy exclusion for twin pregnancy prolongation is unambiguous, and retrospective denials on that indication could add up fast.

---

CPT, HCPCS, and ICD-10 Codes for Progestins Under CPB 0510

Covered CPT Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
11976	CPT	Removal, implantable contraceptive capsules
58300	CPT	Insertion of intrauterine device (IUD)
58301	CPT	Removal of intrauterine device (IUD)

Covered HCPCS Codes (When Selection Criteria Are Met)

Key ICD-10-CM Diagnosis Codes

The full ICD-10-CM code list under CPB 0510 includes 181 codes. The table above covers the primary diagnosis categories most relevant to progestins billing. Access the complete list at the Aetna CPB 0510 source document.

---